Q1 2026 Biocon Ltd Earnings Call Transcript
Key Points
- Biocon Ltd (BOM:532523) successfully completed a qualified institution placement (QIP) of INR4,500 crore, marking its first equity raise since the IPO in 2004, which was oversubscribed, indicating strong investor confidence.
- The company achieved significant regulatory milestones, including the US FDA approval for Kirsty, a biosimilar Insulin Aspart, marking it as the first and only interchangeable rapid-acting insulin in the US.
- Biocon Ltd (BOM:532523) reported a 15% year-on-year growth in operating revenue, driven by accelerated growth in biosimilars, continued growth in CRDMO, and steady performance in generics.
- The company received a Gold rating in the 2024 EcoVadis Corporate Sustainability Assessment, placing it in the top 5% of companies globally, showcasing its commitment to sustainability.
- Biocon Ltd (BOM:532523) secured large tenders, including a multiyear contract with Malaysia's Ministry of Health for RH Insulin and Insulin Glargine, enhancing its market presence in emerging markets.
- The gross margin for Biocon Ltd (BOM:532523) declined by 150 basis points, raising concerns about the profitability of incremental sales, especially in the biosimilars segment.
- Interest expenses have increased, with a net debt of approximately $1.1 billion at the Biocon Biologics level, impacting the company's financial performance.
- The generics segment faced pressure due to the absence of Lenalidomide sales in the current quarter, impacting EBITDA levels both year-on-year and sequentially.
- Operational costs related to new facilities, including the peptide API plant and expanded fermentation capacity, are impacting margins in the near term.
- The company faces challenges in the US adalimumab market, with pricing trends softening and competition affecting market share gains.
Good morning, everyone. Thank you for joining us on this call to discuss Biocon's first quarter results for FY26. I'm Saurabh Paliwal from Biocon's Investor Relations team. Before we get started, let me introduce the management team on this call. We have today Biocon Chairperson, Dr. Kiran Mazumdar-Shaw; Mr. Siddharth Mittal, CEO and Managing Director of Biocon Limited; Mr. Shreehas Tambe, CEO and Managing Director of Biocon Biologics along with other senior management colleagues across our business segments.
A few housekeeping points. We will start the call with the opening remarks by Kiran, which will be followed by an interactive Q&A session. (Event Instructions) Please note that this webinar is being recorded. The recording will be made available on our website within a day, and the call transcript will be made available subsequently.
Before we begin, I want to remind everyone about the Safe Harbor related to today's call. Comments made during the call may be forward-looking in nature and must be viewed in relation to the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
